US FDA approves the first immunotherapy for extensive-stage small-cell lung cancer

Written by Jade Parker, Senior Editor

  1.0.0.20 The US FDA have approved Tecentriq® (atezolizumab) in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small-cell lung cancer (ES-SCLC). Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved for the initial treatment of ES-SCLC.  The approval also marks the first new initial treatment option approved by the FDA for ES-SCLC patients in more than 20 years. “Tecentriq is the first cancer immunotherapy approved for the initial treatment of ES-SCLC, which is especially difficult to treat,” commented Sandra Horning, Roche’s Chief Medical Officer and...

To view this content, please register now for access

It's completely free